Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Insider and Institutional Ownership
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Lyell Immunopharma has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -794,858.12% | -85.71% | -66.41% |
| Xenetic Biosciences | -70.03% | -39.28% | -33.47% |
Valuation & Earnings
This table compares Lyell Immunopharma and Xenetic Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $40,000.00 | 6,771.53 | -$274.45 million | ($13.80) | -0.84 |
| Xenetic Biosciences | $2.98 million | 2.26 | -$2.68 million | ($1.20) | -2.45 |
Xenetic Biosciences has higher revenue and earnings than Lyell Immunopharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Lyell Immunopharma and Xenetic Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 1 | 4 | 1 | 2.71 |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Lyell Immunopharma currently has a consensus target price of $43.00, indicating a potential upside of 270.37%. Given Lyell Immunopharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Lyell Immunopharma is more favorable than Xenetic Biosciences.
Summary
Xenetic Biosciences beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
